Anagrelide

SKU: orb1224250

Description

Anagrelide is a Platelet-reducing Agent. The mechanism of action of anagrelide is as a Phosphodiesterase 3 Inhibitor.

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 68475-42-3
• MW: 256.09
• Purity: >98% (HPLC)
• Formula: C₁₀H₇Cl₂N₃O
• SMILES: C1C2=C(C=CC(=C2Cl)Cl)NC3=NC(=O)CN31
• Target: PDE
• Solubility: DMSO: 10 mM

Bioactivity

• In Vivo:
  Animal model: Adult female athymic mice bearing GIST2B, GIST3, GIST9, GIST882 model. Dosage: 5 mg/kg. Administration: Twice daily; for 10 days. Result: Inhibited or reduced tumor growth in three (GIST2B, GIST9, GIST882) of these four models.
• In Vitro:
  Cell Proliferation Assay Cell line: Megakaryocytic and non-megakaryocytic cells. Concentration: 0.05, 0.3, 1 μM Incubation time: 12-day. Result: Inhibited only megakaryocytic cell growth at every concentration testedCell Cytotoxicity Assay Cell line: GIST882 and GIST48 cell line. Concentration: 0.1, 1, 10, 100, 1000, 10000 nM Incubation time: Result: Induced a cytotoxic effect in the GIST882 cell line (IC50 = 16 nM), but was only weakly active in the GIST48 cell line.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Agrelin | Agrylin | Anagrelide | Anagrelide | BL 4162A | Xagrid | Shire | Thromboreductin

Quick Database Links

Gene Symbol

PDE